PolyPid Ltd. Logo

PolyPid Ltd.

Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.

PYPD | US

Overview

Corporate Details

ISIN(s):
IL0011326795
LEI:
Country:
United States of America
Address:
18 HASIVIM STREET, 4959376 PETACH TIKVA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPid Ltd. is a late-stage biopharmaceutical company focused on developing and commercializing locally administered therapies to improve surgical outcomes. The company's proprietary PLEX™ (Polymer-Lipid Encapsulation) technology is a drug delivery platform designed for the localized, controlled, and prolonged release of therapeutic agents. Its lead product candidate, D-PLEX₁₀₀, is in advanced clinical development for the prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PolyPid is also leveraging its PLEX platform to expand its pipeline into other high-value markets, including oncology and metabolic diseases, with a long-acting GLP-1 receptor agonist delivery system for the diabetes and weight loss market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PolyPid Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PolyPid Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PolyPid Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan
4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden
KLAR
Klotho Neurosciences, Inc. Logo
Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.
United States of America
KLTO
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan
9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan
4967
Kodiak Sciences Inc. Logo
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
United States of America
KOD
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan
177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea
102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America
950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea
041960

Talk to a Data Expert

Have a question? We'll get back to you promptly.